Genprex, Inc.

NASDAQ:GNPX

0.74 (USD) • At close January 14, 2025
Bedrijfsnaam Genprex, Inc.
Symbool GNPX
Munteenheid USD
Prijs 0.738
Beurswaarde 6,278,956
Dividendpercentage 0%
52-weken bereik 0.281 - 13
Industrie Biotechnology
Sector Healthcare
CEO Mr. John Rodney Varner
Website https://www.genprex.com

An error occurred while fetching data.

Over Genprex, Inc.

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc.

Vergelijkbare Aandelen

Cardiol Therapeutics Inc. logo

Cardiol Therapeutics Inc.

CRDL

1.25 USD

Merrimack Pharmaceuticals, Inc. logo

Merrimack Pharmaceuticals, Inc.

MACK

15.145 USD

Sientra, Inc. logo

Sientra, Inc.

SIEN

0.174 USD

TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc.

TCRX

2.63 USD

IceCure Medical Ltd logo

IceCure Medical Ltd

ICCM

1.24 USD

Anebulo Pharmaceuticals, Inc. logo

Anebulo Pharmaceuticals, Inc.

ANEB

1.596 USD

Harpoon Therapeutics, Inc. logo

Harpoon Therapeutics, Inc.

HARP

23.01 USD

HCW Biologics Inc. logo

HCW Biologics Inc.

HCWB

0.342 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)